(UHT) Universal Health Realty - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 575m USD | Total Return: 11.1% in 12m
Avg Turnover: 2.53M
EPS Trend: 28.8%
Rev. Trend: 71.9%
Warnings
High Debt/EBITDA (6.1) with thin interest coverage (1.3)
Altman Z'' -4.75 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Universal Health Realty Income Trust (NYSE: UHT) is a real estate investment trust (REIT) specializing in healthcare and human-service infrastructure. Its portfolio consists of 76 properties across 21 states, including acute care and behavioral health hospitals, medical office buildings, and childcare centers.
The company operates under a business model focused on triple-net leases and master lease agreements, which typically shift property-level expenses like taxes and maintenance to the tenants. Healthcare REITs often benefit from demographic tailwinds, such as an aging population, which sustains demand for clinical and specialized medical space.
Investors can evaluate the long-term dividend sustainability of this trust by reviewing the detailed financial metrics available on ValueRay.
- Dividend yield spread relative to Treasury rates dictates investor capital inflows
- Medical office building occupancy levels maintain core cash flow stability
- Interest rate environment impacts debt refinancing costs and acquisition margins
- Geographic concentration in twenty-one states creates localized regulatory and reimbursement risks
- Relationships with UHS-affiliated operators drive long-term master lease renewal security
| Net Income: 17.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.61 > 1.0 |
| NWC/Revenue: -238.0% < 20% (prev -243.6%; Δ 5.66% < -1%) |
| CFO/TA 0.09 > 3% & CFO 49.4m > Net Income 17.9m |
| Net Debt (393.5m) to EBITDA (64.1m): 6.14 < 3 |
| Current Ratio: 0.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 0.17% < -2% |
| Gross Margin: 90.49% > 18% (prev 0.94%; Δ 8.95k% > 0.5%) |
| Asset Turnover: 26.14% > 50% (prev 17.16%; Δ 8.98% > 0%) |
| Interest Coverage Ratio: 1.25 > 6 (EBITDA TTM 64.1m / Interest Expense TTM 28.1m) |
| A: -0.63 (Total Current Assets 20.2m - Total Current Liabilities 374.0m) / Total Assets 563.8m |
| B: -0.23 (Retained Earnings -126.9m / Total Assets 563.8m) |
| C: 0.06 (EBIT TTM 35.1m / Avg Total Assets 568.6m) |
| D: -0.30 (Book Value of Equity -124.6m / Total Liabilities 416.0m) |
| Altman-Z'' = -4.75 = D |
| DSRI: 0.08 (Receivables 13.2m/113.3m, Revenue 148.7m/98.4m) |
| GMI: 1.04 (GM 90.49% / 94.40%) |
| AQI: 1.22 (AQ_t 0.94 / AQ_t-1 0.77) |
| SGI: 1.51 (Revenue 148.7m / 98.4m) |
| TATA: -0.06 (NI 17.9m - CFO 49.4m) / TA 563.8m) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of June 02, 2026, the stock is trading at USD 40.61 with a total of 74,919 shares traded.
Over the past week, the price has changed by -1.59%,
over one month by +1.84%,
over three months by -4.25% and
over the past year by +11.06%.
Universal Health Realty has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy UHT.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | 3.4% |
P/E Trailing = 32.3828
P/E Forward = 38.7597
P/S = 5.6962
P/B = 3.8913
P/EG = 0.6292
Revenue TTM = 148.7m USD
EBIT TTM = 35.1m USD
EBITDA TTM = 64.1m USD
Long Term Debt = 18.3m USD (from longTermDebt, last quarter)
Short Term Debt = 359.5m USD (from shortLongTermDebt, last quarter)
Debt = 400.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.4m
Net Debt = 393.5m USD (calculated: Debt 400.6m - CCE 7.06m)
Enterprise Value = 968.7m USD (575.1m + Debt 400.6m - CCE 7.06m)
Interest Coverage Ratio = 1.25 (Ebit TTM 35.1m / Interest Expense TTM 28.1m)
EV/FCF = 19.60x (Enterprise Value 968.7m / FCF TTM 49.4m)
FCF Yield = 5.10% (FCF TTM 49.4m / Enterprise Value 968.7m)
FCF Margin = 33.25% (FCF TTM 49.4m / Revenue TTM 148.7m)
Net Margin = 12.01% (Net Income TTM 17.9m / Revenue TTM 148.7m)
Gross Margin = 90.49% ((Revenue TTM 148.7m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Gross Margin QoQ = 70.59% (prev 94.43%)
Tobins Q-Ratio = 1.72 (Enterprise Value 968.7m / Total Assets 563.8m)
Interest Expense / Debt = 7.01% (Interest Expense 28.1m / Debt 400.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = 27.8m (EBIT 35.1m * (1 - 21.00%))
Current Ratio = 0.05 (Total Current Assets 20.2m / Total Current Liabilities 374.0m)
Debt / Equity = 2.71 (Debt 400.6m / totalStockholderEquity, last quarter 147.8m)
Debt / EBITDA = 6.14 (Net Debt 393.5m / EBITDA 64.1m)
Debt / FCF = 7.96 (Net Debt 393.5m / FCF TTM 49.4m)
Total Stockholder Equity = 156.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 17.9m / Total Assets 563.8m)
RoE = 6.31% (Net Income TTM 17.9m / Total Stockholder Equity 282.8m)
RoCE = 11.67% (EBIT 35.1m / Capital Employed (Equity 282.8m + L.T.Debt 18.3m))
RoIC = 15.09% (NOPAT 27.8m / Invested Capital 184.0m)
WACC = 6.27% (E(575.1m)/V(975.7m) * Re(6.78%) + D(400.6m)/V(975.7m) * Rd(7.01%) * (1-Tc(0.21)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 76.16% ; FCFF base≈48.4m ; Y1≈50.9m ; Y5≈59.0m
[DCF] Fair Price = 37.20 (EV 909.6m - Net Debt 393.5m = Equity 516.1m / Shares 13.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.66% → 2.50% )
EPS Correlation: 28.80 | EPS CAGR: 1.93% | SUE: N/A | # QB: 0
Revenue Correlation: 71.89 | Revenue CAGR: 14.13% | SUE: N/A | # QB: 0